›› 2013, Vol. 28 ›› Issue (10): 952-953.DOI: 10.3969/j.issn.1673-8640.2013.10.022
• Orignal Article • Previous Articles Next Articles
Received:2013-02-23
Online:2013-10-30
Published:2013-10-29
CLC Number:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2013.10.022
| [1] 郭 玮,吴 炯,唐文佳,等.不同时段尿白蛋白在诊断早期糖尿病肾脏损伤中的应用[J].中华检验医学杂志,2009,32(10):1091-1095. [2] World Health Organization. Definition,Dignosis and classification of diabetes mellitus and it′s complications[R]. Geneva: WHO, 1999. [3] 中华医学会糖尿病学分会.中国2型糖尿病防治指南(2010年版)[M].第1版.北京:北京大学医学出版社,2011:5. [4] Massy ZA,Ceballos I,Chadefaux-Vekemens B,et al.Homocyst(e)ine, oxidative stress, and endothelium function in uremic patients[J].Kidney Int Suppl,2001,78:S243-S245. [5] 喻长法,张仙森,王丽君,等.尿微量蛋白及血清半胱氨酸蛋白酶抑制剂C的检测对糖尿病肾病的早期诊断价值[J].检验医学,2009,24(6):478-479. [6] 刘义明,黄日安,莫 伟.糖尿病肾病患者尿微量白蛋白、免疫球蛋白G、转铁蛋白和视黄醇结合蛋白的检测及意义[J].广东医学院学报,2009,27(1):35-36. [7] 高 阳,陈思娇,杨红艳,等. 糖尿病肾病患者尿微量清蛋白与肌酐比值的相关因素研究[J].中国全科医学,2011,14(6):598-600. |
| [1] | FAN Lieying. Research status and application prospects of biomarkers for membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1111-1114. |
| [2] | SUN Lincheng, LI Jianfeng, CHENG Weili, JI Panyun. Roles of anti-PLA2R IgG4 antibody and PLA2R IgG4/IgG ratio in primary membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1115-1120. |
| [3] | LIU Qingyang, YUAN Jianming, XIA Jinjun, JIANG Fengying, WANG Qiubo, WANG Xiaoming. CXCL9 as a potential diagnostic marker of rheumatoid arthritis based on GEO database and experimental verification [J]. Laboratory Medicine, 2023, 38(12): 1121-1129. |
| [4] | YANG Xiao, LI Enling, WU Lixia, DAI Yingxin, WANG Zhiqing, HUANG Hao, ZHENG Bing. Influence of cytoplasmic antinuclear antibody on indirect immunofluorescence assay based antineutrophil cytoplasmic antibody determination [J]. Laboratory Medicine, 2023, 38(12): 1135-1140. |
| [5] | XIANG Jin, LIU Aiping, HU Yao, WU Zhiyuan, CAO Guojun, GUAN Ming. ANA profiles in COVID-19 patients and influence of serum heat-inactivation on ANA determination [J]. Laboratory Medicine, 2023, 38(12): 1141-1146. |
| [6] | CHENG Yu, XU Zhen, LU Liu, DING Menglei, YU Shanshan, ZONG Ming, FAN Lieying. Expression and risk factors of anti-ACE-2 antibody in serum of patients with COVID-19 [J]. Laboratory Medicine, 2023, 38(12): 1147-1152. |
| [7] | . [J]. Laboratory Medicine, 2023, 38(12): 1153-1156. |
| [8] | . [J]. Laboratory Medicine, 2023, 38(12): 1157-1159. |
| [9] | WANG Hongling, LIU Mengna, BAI Ping, LIAO Huanjin. Risk factors of relapse following allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia [J]. Laboratory Medicine, 2023, 38(12): 1160-1166. |
| [10] | YANG Xilan, WANG Jinyu, LIU Shuyu, ZHAN Yiyang, LIU Jing, JIA Jian. Correlation between hyperlipidemia and endothelial microparticles in elderly patients from Gulou Community in Nanjing [J]. Laboratory Medicine, 2023, 38(12): 1167-1172. |
| [11] | DAI Fangfang, LU Xinxin, YU Yanhua, CHEN Ming, SUN Guizhen. Analysis of Mycobacterium infection in HIV/AIDS patients [J]. Laboratory Medicine, 2023, 38(12): 1173-1176. |
| [12] | GU Yu, LIANG Xiaoyan, MA Shenghui, TONG Na, CHENG Mingyan, YAN Zejun. Expression and near-term prognostic predictive value of plasma biomarkers in chronic kidney disease patients with thromboembolism [J]. Laboratory Medicine, 2023, 38(12): 1177-1182. |
| [13] | . [J]. Laboratory Medicine, 2023, 38(12): 1183-1185. |
| [14] | . [J]. Laboratory Medicine, 2023, 38(12): 1186-1190. |
| [15] | . [J]. Laboratory Medicine, 2023, 38(12): 1191-1194. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
